川上 由育Yoshiiku Kawakami

Last Updated :2017/09/01

所属・職名
病院総合医療研究推進センター 総合医療研究推進センター 准教授
メールアドレス
kamy4419hiroshima-u.ac.jp

基本情報

学位

  • 博士(医学) (広島大学)

研究分野

  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

研究キーワード

  • 臨床試験
  • 肝癌
  • 肝炎

所属学会

教育活動

授業担当

  1. 2017年, 学部専門, 集中, 器官・システム病態制御学I
  2. 2017年, 学部専門, 集中, 症候診断治療学
  3. 2017年, 学部専門, 集中, 臨床実習・臨床実践学
  4. 2017年, 学部専門, 集中, 臨床実習入門プログラム
  5. 2017年, 学部専門, 集中, アドバンスト医学実習
  6. 2017年, 修士課程・博士課程前期, セメスター(後期), 臨床研究方法論
  7. 2017年, 博士課程・博士課程後期, セメスター(後期), 臨床研究の基礎および実践

研究活動

学術論文(★は代表的な論文)

  1. Expression of telomerase component genes in hepatocellular carcinomas., Eur. J. Cancer, 496巻, 502号, 2000
  2. Precancerous hepatic nodules had significant levels of telomerase activity by sensitive quantitation using hybridization protection assay., Cancer, 312巻, 317号, 2000
  3. Telomere reduction in human liver tissues with age and chronic inflammation., Exp Cell Res, 578巻, 582号, 2000
  4. ★, Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues., Oncogene, 3888巻, 3893号, 2000
  5. Macrophase-colony stimulating factor inhibits the growth of human ovarian cancer cells in vitro., Eur. J. Cancer, 1991巻, 1997号, 2000
  6. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma : Comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion, Journal of Vascular and Interventional Radiology, 847巻, 854号, 2001
  7. Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and vinca alkaloids of human ovarian cancer cells., Anticancer Res., 2537巻, 2546号, 2001
  8. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemarrhage, American Journal of Roentgenology, 1167巻, 1174号, 2002
  9. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma., Am J Surg., 284巻, 290号, 2002
  10. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan., Scand J Gastroenterol., 894巻, 900号, 2003
  11. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping., J Med Virol., 558巻, 565号, 2004
  12. 門脈腫瘍栓合併肝細胞癌に対する肝動注化学療法が著効した後に出現した門脈大循環脳症にB-RTOが有効であった1例, 日本門脈圧亢進症学会雑誌, 196巻, 197号, 2006
  13. 肝炎・肝硬変の最新の知見;B型慢性肝炎の治療方針, クリニシアン, 143巻, 147号, 2006
  14. Peg-IFNα2b+Ribavirin併用療法におけるエイコサペンタエン酸の貧血抑制効果?多施設共同無作為化比較実験?, 消化器科, 487巻, 492号, 2006
  15. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology, 1179巻, 1186号, 2007
  16. The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration., J Gastroenterol., 663巻, 672号, 2007
  17. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma., World J Gastroenterol., 5188巻, 5195号, 2007
  18. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma., World J Gastroenterol., 5343巻, 5350号, 2007
  19. Balloon-occluded retrograde transvenous obliteration for portal-systemic encephalopathy due to superior mesenteric-caval shunt via the right gonadal vein., Intern Med., 1479巻, 1480号, 2007
  20. Efficacy of percutaneous cementoplasty for bone metastasis from hepatocellular carcinoma., Oncology., 285巻, 292号, 2007
  21. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial., Intervirology., 439巻, 446号, 2007
  22. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma., Liver International., 1209巻, 1216号, 2007
  23. A Case of Fulminant Hepatic Failure Caused by Hepatitis E virus79117, Clinical Journal of gastroenterology, 69巻, 74号, 2008
  24. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center., J Gastroenterol Hepatol., 1216巻, 1222号, 2008
  25. Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy., J Gastroenterol Hepatol., 541巻, 545号, 2008
  26. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma., J Gastroenterol., 550巻, 557号, 2008
  27. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases., Oncology., 41502巻, 2008
  28. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient., Hepatol Res., 415巻, 420号, 2009
  29. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis., J Gastroenterol., 492巻, 502号, 2009
  30. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma., Hepatol Res., 2009
  31. ★, Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naive Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial., J Gastroenterol Hepatol., 366巻, 371号, 2009
  32. The first Japanese case of COACH syndrome., Hepatol Res., 318巻, 323号, 2009
  33. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy., J Med Virol., 640巻, 649号, 2009
  34. Predicting the response to 48-week combination therapy with peginterferon alpha-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients., Hepatol Res., 531巻, 538号, 2009
  35. 「臨床研究に関する倫理指針」改正への対応, 広島医学, 727巻, 732号, 2010
  36. Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases., Hepatogastroenterology., 1272巻, 1278号, 2010
  37. Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma., Hepatol Res.巻, 2010
  38. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases., J Gastroenterol Hepatol., 1117巻, 1122号, 2010
  39. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino, Scand J Gastroenterol., 1488巻, 1496号, 2010
  40. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antivir Ther., 2010
  41. Evaluation of portosystemic collaterals by MDCT-MPR imaging for management of hemorrhagic esophageal varices., 239巻, 245号, 2010
  42. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrob Agents Chemother., 2010
  43. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy., J Med Virol., 1048巻, 1057号, 2011
  44. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region., Hepatol Res., 1126巻, 1131号, 2011
  45. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma., J Viral Hepat., e550-560巻, 2011
  46. Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus., Hepatol Res., 1046巻, 1056号, 2011
  47. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy., J Gastroenterol., 799巻, 808号, 2011
  48. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations., J Gen Virol., 1071巻, 1081号, 2011
  49. Recent trend of clinical features in patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 368巻, 375号, 2012
  50. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon alpha-2b to alpha-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report, INTERVIROLOGY, 306巻, 310号, 2012
  51. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators, NATURE GENETICS, 760巻, U182号, 2012
  52. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1467巻, 1472号, 2012
  53. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 2012
  54. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines, JOURNAL OF GASTROENTEROLOGY, 1巻, 12号, 2013
  55. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b, JOURNAL OF VIRAL HEPATITIS, 167巻, 173号, 2013
  56. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir, JOURNAL OF HEPATOLOGY, 646巻, 654号, 2013
  57. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options, JOURNAL OF HEPATOLOGY, 655巻, 662号, 2013
  58. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 847巻, 855号, 2013
  59. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLOS ONE, 2013
  60. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases, HEPATOLOGY RESEARCH, 1182巻, 1189号, 2013
  61. Response to "treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'?"., J Gastroenterol., 557巻, 558号, 2013
  62. Percutaneous Transvenous Embolization for Portal-Systemic Shunts associated with Encephalopathy: Long-term outcomes in 14 patients., Hepatol Res., 2013
  63. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients., Hepatol Res., 2013
  64. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, J Gastroenterol, 2013
  65. ★, Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT, Antivir Ther, 2013
  66. ★, Letter: pitavastatin supplementation of PEG-IFN/ribavirin improves sustained virological response against HCV.”,, Aliment Pharmacol Ther, 443巻, 444号, 2014
  67. Two patients treated with PEGIFN/RBV/TVR triple therapy for recurrent hepatitis C after living donor liver transplantation, Hepatol Res, 2014
  68. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1035巻, 1042号, 2014
  69. ★, Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial, JOURNAL OF VIRAL HEPATITIS, 348巻, 356号, 2014
  70. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 323巻, 328号, 2014
  71. Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection, HEPATOLOGY, 2083巻, 2091号, 2014
  72. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib, HEPATOLOGY RESEARCH, 1320巻, 1328号, 2014
  73. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, E420巻, E427号, 2014
  74. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, E447巻, E454号, 2014
  75. Integrated Analysis of Whole Genome and Transcriptome Sequencing Reveals Diverse Transcriptomic Aberrations Driven by Somatic Genomic Changes in Liver Cancers, PLOS ONE, 2014
  76. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 273巻, 287号, 2015
  77. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity, Nature Communications, 2015
  78. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: Propensity score-matched analysis, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 337巻, 344号, 2015
  79. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 726巻, 732号, 2015
  80. Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report, TRANSPLANTATION PROCEEDINGS, 809巻, 814号, 2015
  81. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 607巻, 617号, 2015
  82. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report, HEPATOLOGY RESEARCH, 705巻, 710号, 2015
  83. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 656巻, 662号, 2015
  84. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases, EUROPEAN JOURNAL OF RADIOLOGY, 1540巻, 1545号, 2015
  85. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 554巻, 563号, 2015
  86. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms, ADVANCES IN THERAPY, 637巻, 649号, 2015
  87. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 1913巻, 1920号, 2015
  88. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma, JOURNAL OF DIGESTIVE DISEASES, 505巻, 512号, 2015
  89. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 3272巻, 3281号, 2015
  90. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation, HEPATOLOGY RESEARCH, 1047巻, 1054号, 2015
  91. Randomized comparison of daclatasvir plus asunaprevir versus telaprevir plus peginterferon/ribavirin in Japanese hepatitis C virus patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 14巻, 22号, 2016
  92. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus, HEPATOLOGY RESEARCH, E146巻, E153号, 2016
  93. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31巻, 5号, pp.1009-pp.1015, MAY 2016
  94. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer, NATURE GENETICS, 48巻, 5号, pp.500-pp.+, MAY 2016
  95. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization, ANTICANCER RESEARCH, 36巻, 7号, pp.3523-pp.3529, JUL 2016
  96. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 46巻, 8号, pp.758-pp.764, JUL 2016
  97. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46巻, 9号, pp.944-pp.948, AUG 2016
  98. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report, HEPATOLOGY RESEARCH, 46巻, 7号, pp.707-pp.712, JUN 2016